Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Magnolo N, Cameron MC, Shahriari M, Geng B, Calimlim BM, Teixeira H, Hu X, Yang Y, Liu Y, Zhang S, Sancho Sanchez C, Altman K, Langley RG. Magnolo N, et al. Among authors: langley rg. J Dermatolog Treat. 2024 Dec;35(1):2344589. doi: 10.1080/09546634.2024.2344589. Epub 2024 May 2. J Dermatolog Treat. 2024. PMID: 38697950 Free article. Clinical Trial.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Among authors: langley rg. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group. McInnes IB, et al. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. Lancet. 2013. PMID: 23769296 Clinical Trial.
Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Silverberg JI, Eichenfield LF, Blauvelt A, Irvine AD, Guttman-Yassky E, Langley RG, Warren RB, French LE, Felding J, Weiss A, Pedersen CB, Jensen ML, Carlsson A, Sommer MOA, Kjøller K, Simpson EL. Silverberg JI, et al. Among authors: langley rg. Br J Dermatol. 2025 Jan 7:ljae507. doi: 10.1093/bjd/ljae507. Online ahead of print. Br J Dermatol. 2025. PMID: 39847538
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
Blauvelt A, Chen Y, Branigan PJ, Liu X, DePrimo S, Keyes BE, Leung M, Fakharzadeh S, Yang YW, Muñoz-Elías EJ, Krueger JG, Langley RG. Blauvelt A, et al. Among authors: langley rg. JID Innov. 2024 Jun 26;4(5):100297. doi: 10.1016/j.xjidi.2024.100297. eCollection 2024 Sep. JID Innov. 2024. PMID: 39224116 Free PMC article.
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.
Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA, Prinz JC, Londono-Garcia A, Nast A, Santin M, Goletti D, Abreu M, Spuls P, Boehncke WH, Puig L. Torres T, et al. Among authors: langley rg. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):52-69. doi: 10.1111/jdv.20287. Epub 2024 Aug 16. J Eur Acad Dermatol Venereol. 2025. PMID: 39149807 Review.
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J, Shah M, Zakria D, Armstrong AW, Golant AK, Gottlieb AB, Weinberg JM, Kircik L, Han G, Langley RG, Neimann AL, Lebwohl M. Burshtein J, et al. Among authors: langley rg. J Drugs Dermatol. 2024 Aug 1;23(8):592-599. doi: 10.36849/JDD.8246. J Drugs Dermatol. 2024. PMID: 39093660 Review.
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Blauvelt A, et al. Among authors: langley rg. J Invest Dermatol. 2024 Dec;144(12):2816-2819.e2. doi: 10.1016/j.jid.2024.05.020. Epub 2024 Jun 25. J Invest Dermatol. 2024. PMID: 38936766 Free article. No abstract available.
195 results